16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis; multiple sclerosis (MS) Cell culture and mouse studies suggest inhibiting autophagy in T cells could treat juvenile idiopathic arthritis (JIA), MS and other autoimmune diseases. In activated primary CD4+ T cells from the synovial...
23:52 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4+ T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that blocks...
16:56 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

Merck & Co. Inc. (NYSE:MRK) said once-daily oral doravirine (MK-1439) in combination with other antiretroviral therapies (ARTs) led to viral suppression at week 96 in 73.1% of patients vs. 66% of patients treated with ritonavir-boosted...
18:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

ViiV presents detailed Phase III primary endpoint data for two-drug HIV regimen

ViiV Healthcare Ltd. (Brentford, U.K.) presented pooled additional data from a pair of Phase III trials in HIV-1 infected patients showing that its two-drug regimen of dolutegravir and lamivudine led to HIV-1 RNA levels of...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
19:05 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Mouse studies suggest an RNA-based vaccine encoding Plasmodium MIF could help prevent malaria infection. The vaccine consists of a lipid nanoparticle (LNP) loaded with Plasmodium MIF encoded by an alphaviral RNA replicon. In mouse...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
22:55 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8+ T cells have grabbed most of the attention, a study from...